Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Tesmilifene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 known ✓ | P35462 | 3/20 | 0.61 |
| ▸ | DRD1 known ✓ | P21728 | 2/20 | 0.61 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.61 |
| ▸ | ESR1 known ✓ | P03372 | 4/20 | 0.56 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 3/20 | 0.56 |
| ▸ | KCNH2 known ✓ | Q12809 | 3/20 | 0.56 |
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.56 |
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.56 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.56 |
| ▸ | PTGS1 known ✓ | P23219 | 2/20 | 0.56 |
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.56 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.56 |
| ▸ | HTR6 known ✓ | P50406 | 2/20 | 0.56 |
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 0.56 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 2/20 | 0.56 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.56 |
| ▸ | ERBB2 known ✓ | P04626 | 1/20 | 0.56 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 0.56 |
| ▸ | CHRM5 known ✓ | P08912 | 1/20 | 0.56 |
| ▸ | ADRB3 known ✓ | P13945 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tesmilifene SCHEMBL112525 | 0.98 | LTA4H (1.00) | LTA4HCYP2D6HTTCYP1A2CYP2C9 | |
| Tesmilifene SCHEMBL1650386 | 0.95 | LTA4H (0.94) | LTA4HCYP2D6HTTCYP1A2CYP2C9 | |
| Hydrochloric Acid SCHEMBL10503798 | 0.90 | CYP2D6 (0.79) | LTA4HCYP2D6HTTCYP1A2CYP2C9 | |
| Tesmilifene SCHEMBL2790746 | 0.89 | LTA4H (0.77) | LTA4HCYP2D6HTTCYP1A2CYP2C9 | |
| Hydrochloric Acid SCHEMBL10505479 | 0.86 | CYP2D6 (0.72) | LTA4HCYP2D6HTTCYP1A2CYP2C9 | |
| SCHEMBL4688380 | 0.85 | LTA4H (0.77) | LTA4HCYP2D6HTTCYP1A2CYP2C9 | |
| SCHEMBL12610941 | 0.84 | CYP2D6 (0.74) | LTA4HCYP2D6HTTCYP1A2CYP2C9 | |
| SCHEMBL1405290 | 0.84 | CYP2D6 (0.74) | LTA4HCYP2D6HTTCYP1A2CYP2C9 | |
| Bromide SCHEMBL1173547 | 0.83 | CYP2D6 (0.72) | LTA4HCYP2D6HTTCYP1A2CYP2C9 | |
| SCHEMBL9706125 | 0.82 | EBP (0.72) | LTA4HCYP2D6HTTCYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4634 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747263-A1 | LIPID NANOPARTICLES AND USES THEREOF | University of Connecticut (US) | 2026-05-27 | — | — | EP | claimed |
| US-12636252-B2 | Process of preparing mRNA-loaded lipid nano particles | TRANSLATE BIO, INC. (US) | 2026-05-26 | — | — | US | claimed |
| WO-2026104818-A1 | COMPLEX | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2026-05-21 | — | — | WO | claimed |
| US-20260139254-A1 | INTERFERING RNA FOR INHIBITING TOP1 GENE EXPRESSION AND USE THEREOF | JENKEM TECH CO LTD BEIJING (CN) | 2026-05-21 | — | — | US | claimed |
| US-20260137629-A1 | Novel Lipids For Delivery Of Nucleic Acid Segments | ASTRAZENECA AB (SE) | 2026-05-21 | — | — | US | claimed |
| US-12629387-B2 | Composition of antiviral agent for use in prophylactic or post-exposure treatment of infectious or respiratory diseases | INSPIRMED CORP. (TW) | 2026-05-19 | — | — | US | claimed |
| CN-122057051-A | Preparation method of novel ultrasonic contrast agent for protecting unstable arterial plaque | 中国人民武装警察部队吉林省总队医院 | 2026-05-19 | — | — | CN | claimed |
| WO-2026101232-A1 | POLYMER COMPOUND FOR CELL SURFACE MODIFICATION FOR IMPROVING DRUG DELIVERY EFFICIENCY | 동국대학교 산학협력단 | 2026-05-15 | — | — | WO | claimed |
| CN-122031434-A | Active oxygen response type targeted liposome dual-drug co-delivery system for treating pulmonary fibrosis and preparation method and application thereof | 武汉大学 | 2026-05-15 | — | — | CN | claimed |
| WO-2026098601-A1 | LIPID NANOPARTICLE FOR DELIVERING LOAD | 北京剂泰生命科技有限公司 | 2026-05-15 | — | — | WO | claimed |
| CN-114088675-A | Immunoliposome wrapping fluorescent dye and application | 浙江科技学院 | 2022-02-25 | — | — | CN | claimed |
| US-20220054429-A1 | COMPOSITIONS COMPRISING CANNABIDIOL AND SECOND THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER | AKOS BIOSCIENCES, INC. | 2022-02-24 | — | — | US | claimed |
| CN-114072446-A | Polymer dots | 生物辐射实验室股份有限公司 | 2022-02-18 | — | — | CN | claimed |
| CN-114040750-A | Inhalable bronchodilator sustained-release composition for treating pulmonary diseases | 盈擘医药股份有限公司 | 2022-02-11 | — | — | CN | claimed |
| WO-2022023456-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NANO EMBEDDED MICROPARTICLES AND METHODS OF USE | ASTRAZENECA AB (SE) | 2022-02-03 | — | — | WO | claimed |
| CN-114007653-A | Drug delivery vehicle and pharmaceutical preparation using the same | 复旦大学 | 2022-02-01 | — | — | CN | claimed |
| WO-2022020542-A1 | TREATMENT AND PREVENTION OF CONDITIONS ASSOCIATED WITH RESPIRATORY DISEASES | UNIVERSITY OF HOUSTON SYSTEM (US) | 2022-01-27 | — | — | WO | claimed |
| US-20220023450-A1 | BONE MARROW-, RETICULOENDOTHELIAL SYSTEM-, AND/OR LYMPH NODE-TARGETED RADIOLABELED LIPOSOMES AND METHODS OF THEIR DIAGNOSTIC AND THERAPEUTIC USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-01-27 | — | — | US | claimed |
| US-20100144660-A1 | USE OF N,N-DIETHYL-2-[-4-(PHENYLMETHYL)-PHENOXY]ETHANAMINE MONOHYDROCHLORIDE (DPPE) IN CANCER THEREAPY | YM BIOSCIENCES INC. (CA) | 2010-06-10 | — | — | US | claimed |
| US-20040248986-A1 | Use of n,n-diethyl-2-{-4-(phenylmethyl) - phenoxy} ethanamine monohydrochloride (dppe) in cancer therapy | MANITOBA, UNIVERSITY OF (CA) | 2004-12-09 | — | — | US | claimed |